We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
-1.87%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$163M
AUM Growth
-$8.83M
Cap. Flow
+$356K
Cap. Flow %
0.22%
Top 10 Hldgs %
92.23%
Holding
44
New
1
Increased
5
Reduced
–
Closed
3

Top Buys

Rank Stock Value
1
VNDA icon
Vanda Pharmaceuticals
VNDA
+$354K
2
VCYT icon
Veracyte
VCYT
+$338K
3
ROKA
Sorrento Tech, Inc. Common Stock
ROKA
+$108K
4
GNMX
Aevi Genomic Medicine Inc
GNMX
+$73.7K
5
CELGZ
Celgene Corporation Contingent Value Rights
CELGZ
+$60.3K

Top Sells

Rank Stock Value
1
KURA icon
Kura Oncology
KURA
+$369K
2
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$214K
3
TTHI
TRANSITION THERAPEUTICS INC (CANADA)
TTHI
+$36K

Sector Composition

Rank Sector Weight
1 Healthcare 95.77%
2 Energy 3.29%
3 Industrials 0.32%
4 Consumer Staples 0.19%
5 Consumer Discretionary 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$89.9M 55.35%
777,051
– –
AXDX
2
DELISTED
Accelerate Diagnostics
AXDX
$45.1M 27.78%
217,580
– –
EQT icon
3
EQT Corp
EQT
$31B
$2.77M 1.7%
77,705
– –
VRML
4
DELISTED
Vermillion, Inc.
VRML
$2.58M 1.59%
2,717,514
– –
MASI
5
DELISTED
Masimo
MASI
$2.47M 1.52%
36,600
– –
BIOL
6
DELISTED
Biolase, Inc.
BIOL
$1.8M 1.11%
103
– –
OVV icon
7
Ovintiv
OVV
$16.2B
$1.55M 0.96%
26,460
– –
TSRO
8
DELISTED
TESARO, Inc.
TSRO
$1.34M 0.82%
9,950
– –
CFRX
9
DELISTED
ContraFect Corporation
CFRX
$1.27M 0.78%
906
– –
OXFD
10
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$1.01M 0.62%
67,303
– –
NBIX icon
11
Neurocrine Biosciences
NBIX
$17.2B
$975K 0.6%
25,200
– –
MRK icon
12
Merck
MRK
$315B
$883K 0.54%
15,720
– –
QDEL icon
13
QuidelOrtho
QDEL
$1.19B
$835K 0.51%
38,975
– –
NXTM
14
DELISTED
NxStage Medical Inc.
NXTM
$739K 0.45%
28,200
– –
WMGI
15
DELISTED
Wright Medical Group Inc
WMGI
$689K 0.42%
30,000
– –
VCYT icon
16
Veracyte
VCYT
$4.72B
$617K 0.38%
79,767
+45,200
+131% +$338K
CORT icon
17
Corcept Therapeutics
CORT
$9.72B
$581K 0.36%
80,000
– –
OMED
18
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$545K 0.34%
70,689
– –
PXD
19
DELISTED
Pioneer Natural Resource Co.
PXD
$541K 0.33%
3,000
– –
SIEN
20
DELISTED
Sientra, Inc.
SIEN
$539K 0.33%
6,330
– –
SITO
21
DELISTED
SITO MOBILE, LTD
SITO
$517K 0.32%
140,000
– –
CTRA
22
DELISTED
Coterra Energy
CTRA
$491K 0.3%
21,000
– –
ARAY icon
23
Accuray
ARAY
$30.8M
$438K 0.27%
95,300
– –
VNDA icon
24
Vanda Pharmaceuticals
VNDA
$327M
$351K 0.22%
+22,000
New +$354K
XNCR icon
25
Xencor
XNCR
$1.3B
$324K 0.2%
12,300
– –
1
2

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q4 2016 Portfolio in Review

As of Q4 2016, Birchview Capital held 44 positions worth $163M, down 5.2% from $171M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Birchview Capital's Q4 2016 filing shows 1 new, 5 increased and 3 closed positions. Its largest new stake was Vanda Pharmaceuticals: 22,000 shares worth $351K. The largest sale was Kura Oncology, an estimated $369K.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier, followed by Energy and Industrials.

  • Birchview Capital's largest Q4 2016 buy was Vanda Pharmaceuticals: 22,000 shares worth $351K.
  • Birchview Capital added most to Veracyte in Q4 2016, an estimated $338K increase.
  • Birchview Capital fully exited Kura Oncology in Q4 2016, selling an estimated $369K.
  • Birchview Capital's ten largest holdings make up 92% of its $163M portfolio in Q4 2016.
  • Birchview Capital opened 1 new position and closed 3 in Q4 2016.
  • Birchview Capital's portfolio value fell 5.2% quarter-over-quarter to $163M.

Based on Birchview Capital's 13F filing for Q4 2016, filed 9 Feb 2017.